I think we should let our management run with thes
Post# of 153822
(Total Views: 483)
Posted On: 05/30/2021 11:26:02 AM
Re: craigakess #92331
I think we should let our management run with these two new Brazilian trials and the LH’s trial too. They said in their last press release that they learned a wealth of information from the previous trials.
All though some will try to bash them on trial design. The management has yet to explain why they designed the trials the way they did and why and until they have a chance to explain. The bashing to me is just noise and has no scientific basis.
How do we know that in the severe trials that it’s not the dose size but more important the length of time your given Leronlimab that is the most important factor? As an example... how much penicillin and for how long for it to help? Don’t miss a dose while you are instructed to take the whole prescription to not let it have a rebound response. It doesn’t happen overnight for penicillin and the same will probably hold true for Leronlimab.
We know the Leronlimab dosage and receptor occupancy was declining after 14 days and now we have 28 days of dosing. This could be the one thing that sets things the way they should be. Could show to be the miracle drug we all hoped it would show to be. Could it just be more time needed like other drugs need time to have a full effect? We know that dosage levels can be less and response is still a phase 3 primary endpoint previously achieved. How do any of us know that we need to have a larger dose? What does the science say? This is what everyone wants to know. Let Nader and company explain why they allowed the FDA or if it was just science that dictated the change to a smaller dosage on the remaining 3 doses.
The last PR said it best and we should give them the benefit of the doubt until they actually have the chance to explain. The phrase they used I copied and pasted right here...
***We will update investors on the next investment community call on the design of these trials based on the wealth of information we have learned from our previous COVID-19 trials.***
Who is qualified without the information that Cytodyn has to pass judgement before we know why they designed the trials the way they did? My guess is... nobody because we are not privy to the information that is used to design the trials. Makes no sense to pass judgement without all the facts. Would you say that is correct being a lawyer like you are? Facts are important and passing judgement on trial design without facts isn’t proper in anyone’s world and especially not yours being a lawyer.
Having a new CRO and not Amerex for this trial will be another big advancement in my opinion. What has Amerex done for us really? Could they be a bigger part of the problem? Now we have support of a well established trial professionals that will also bode well for us. Support of big pharmaceutical companies in 3 different countries that believe in Leronlimab and will do our bidding for us. These realities have changed the whole landscape for us battling for ourselves and now we have experienced proven pharmaceutical companies doing our bidding for us. I would say we are pretty hooked up right now. If anything is going to go right with the help we now have. We have set ourselves up pretty damn good. I couldn’t be happier that we went international and different CRO and help for foreign big pharmaceutical companies. This is not small steps we have takes. These are huge strides and I believe in the drug Leronlimab to show well in these new trials and for our interim results to be amazing just on the principles of longer dosing.
Craigakess... try to convince me on principles of different management only for what is known and FACTS that the new group could do better than Cytodyn management. I don’t think you can because there is no plan from the other group. Wouldn’t you say that is odd at this late stage in the game?
All though some will try to bash them on trial design. The management has yet to explain why they designed the trials the way they did and why and until they have a chance to explain. The bashing to me is just noise and has no scientific basis.
How do we know that in the severe trials that it’s not the dose size but more important the length of time your given Leronlimab that is the most important factor? As an example... how much penicillin and for how long for it to help? Don’t miss a dose while you are instructed to take the whole prescription to not let it have a rebound response. It doesn’t happen overnight for penicillin and the same will probably hold true for Leronlimab.
We know the Leronlimab dosage and receptor occupancy was declining after 14 days and now we have 28 days of dosing. This could be the one thing that sets things the way they should be. Could show to be the miracle drug we all hoped it would show to be. Could it just be more time needed like other drugs need time to have a full effect? We know that dosage levels can be less and response is still a phase 3 primary endpoint previously achieved. How do any of us know that we need to have a larger dose? What does the science say? This is what everyone wants to know. Let Nader and company explain why they allowed the FDA or if it was just science that dictated the change to a smaller dosage on the remaining 3 doses.
The last PR said it best and we should give them the benefit of the doubt until they actually have the chance to explain. The phrase they used I copied and pasted right here...
***We will update investors on the next investment community call on the design of these trials based on the wealth of information we have learned from our previous COVID-19 trials.***
Who is qualified without the information that Cytodyn has to pass judgement before we know why they designed the trials the way they did? My guess is... nobody because we are not privy to the information that is used to design the trials. Makes no sense to pass judgement without all the facts. Would you say that is correct being a lawyer like you are? Facts are important and passing judgement on trial design without facts isn’t proper in anyone’s world and especially not yours being a lawyer.
Having a new CRO and not Amerex for this trial will be another big advancement in my opinion. What has Amerex done for us really? Could they be a bigger part of the problem? Now we have support of a well established trial professionals that will also bode well for us. Support of big pharmaceutical companies in 3 different countries that believe in Leronlimab and will do our bidding for us. These realities have changed the whole landscape for us battling for ourselves and now we have experienced proven pharmaceutical companies doing our bidding for us. I would say we are pretty hooked up right now. If anything is going to go right with the help we now have. We have set ourselves up pretty damn good. I couldn’t be happier that we went international and different CRO and help for foreign big pharmaceutical companies. This is not small steps we have takes. These are huge strides and I believe in the drug Leronlimab to show well in these new trials and for our interim results to be amazing just on the principles of longer dosing.
Craigakess... try to convince me on principles of different management only for what is known and FACTS that the new group could do better than Cytodyn management. I don’t think you can because there is no plan from the other group. Wouldn’t you say that is odd at this late stage in the game?
(4)
(1)